// App-Quantinova.ai

P447 : The impact of therapeutic drug monitoring during biosimilar infliximab switch in inflammatory bowel disease

Researchers

Presenter

  • R Ranjan

Principal Investigators

  • S Myers

  • L Crissop

  • S Ritchie

  • F Maw

  • S Sebastian

  • A Dhar

Medical Centers

  • County Durham and DarlingtonNHS Foundation Trust, County Durham, UK

  • Hull Royal Infirmary, Gastroenterology, Hull, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Autoimmune (AI)

  • Genetic Disorder

  • Gastroenterology (GU)

Disease

  • Inflammatory bowel disease

  • Ulcerative colitis

  • Crohn's disease

Biomarkers

  • N/A

Drug/Treatment

  • Allmercap

  • Oraprine

  • Methotrexate

  • Infliximab

  • Infliximab Biosimilar

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved